

PharmaForum 2010, am 2. November in Mainz

1. Company

Merck is the world's oldest pharmaceutical and chemical company with approximately 40.000 employees in 64 countries. Its roots date back to 1668, when Friedrich Jacob Merck purchased the "Angel Pharmacy" in Darmstadt – still owned by the Merck family today.

Around 30% of the company's total capital is publicly traded, while the Merck family owns an interest of about 70% via the general partner E. Merck KG. Merck shares have been included in the DAX® 30 since 2007.

In early 2007, the acquisition of the Swiss firm Serono, Europe's leading biopharmaceutical company, was completed. The scope of this strategically compelling combination is expected to raise Merck's competitiveness in the global pharmaceutical market. Analogical, Merck strengthened its chemical sector with the acquisition of Millipore in 2010.

2. Core Competences

2.1 Pharmaceuticals

Merck discovers, develops, manufactures and markets innovative prescription drugs as well as over-the-counter products.

Merck develop therapies for high unmet medical needs. Through their targeted effect, these help patients to live a longer and better life. Our over-the-counter products can prevent disease and relieve minor complaints.

Key therapeutic areas and products

- ⇒ Oncology: Erbitux® (metastatic colorectal cancer, head and neck cancer), UFT® (colorectal cancer)
- ⇒ Neurodegenerative Diseases: Rebif® (multiple sclerosis)
- ⇒ Fertility: Gonal-f®, Ovitrelle®, Pergoveris™, Luveris®, Crinone®, Cetrotide®
- ⇒ Endocrinology: Saizen® (growth hormone disorders), Serostim® (HIV-associated wasting), Kuvan® (phenylketonuria)
- ⇒ CardioMetabolic Care: Glucophage® family (type 2 diabetes), Concor® family (cardiovascular diseases), Euthyrox® (thyroid diseases)
- ⇒ Other therapeutic areas: Cyanokit® (cyanide poisoning) and other products

2.2 Chemicals

With a range of more than 40.000 products, Merck Millipore ranks third in the life science market. The product and services portfolio of the Bioscience business unit consists of protein research assays and reagents, cell culture solutions and drug discovery services for biopharmaceutical companies. The Lab Solution business unit offers a comprehensive range of laboratory chemicals used in research, quality, analytical and clinical laboratories. The process solution business unit is specialized in a variety of applications for the biotechnology, pharmaceutical and food and beverage industries. Furthermore Liquid Crystals are the key product group within the Performance Materials unit.

3. Cooperations offered and requested

Merck Serono constantly seeks:

- Novel therapeutic agents and drug targets in our key therapeutic areas.
- Innovative technologies that can enhance the productivity of our drug discovery activities.

Contact us to submit your opportunity!

Search fields of Merck Serono: Focus on unmet medical needs

- Oncology: Novel targeted anti-cancer approaches, focusing on proliferation and survival signaling pathways, as well as immune intervention strategies.
- Neurodegenerative diseases: Innovative therapies for Multiple Sclerosis, Parkinson's and Alzheimer's diseases.
- Autoimmune and inflammatory diseases: Novel therapies for rheumatoid arthritis, systemic lupus erythematosus, psoriasis, atopic dermatitis, inflammatory bowel diseases and osteoarthritis.
- Fertility: Innovative therapeutics and technologies for treating infertility.
- Endocrinology: Specialized therapies in target indications.